Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19737334 | 0.79 | TDP1 (0.36) | MME | |
| SCHEMBL23205735 | 0.78 | RNPEP (0.43) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 | |
| SCHEMBL3965956 | 0.78 | RNPEP (0.43) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 | |
| SCHEMBL7369164 | 0.78 | RNPEP (0.43) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 | |
| SCHEMBL17772998 | 0.77 | RNPEP (0.41) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 | |
| SCHEMBL23222764 | 0.76 | ECE1 (0.33) | — | |
| SCHEMBL19737333 | 0.76 | CYP1A2 (0.47) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL22383970 | 0.76 | SLC7A5 (0.50) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 | |
| Bicarbonate SCHEMBL27506741 | 0.74 | FFAR3 (0.35) | MEN1LMNAKMT2ACYP2D6CYP2C19 | |
| SCHEMBL7365108 | 0.74 | RNPEP (0.43) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183253-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2023-06-15 | — | — | US | disclosed |
| US-20170362238-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362238-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | POLRMT, NT5C3B, CHMP4B | RNPEP 1698/4885SLC7A5 1398/4885CPA1 1789/4885 |
| US-20230183253-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | POLRMT, NT5C3B, CHMP4B | RNPEP 1698/4885SLC7A5 1398/4885CPA1 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.